Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial
Posted inGastroenterology news Oncology

Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial

The phase 3 TORCH trial demonstrates that adding selective radiofrequency ablation after transarterial chemoembolization significantly improves progression-free and overall survival in patients with unresectable liver-confined hepatocellular carcinoma, with acceptable safety.
Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial
Posted innews Oncology Respiratory

Perioperative Toripalimab Enhances Surgical Outcomes and Survival in Stage III Resectable NSCLC: Insights from the Neotorch Trial

This post hoc analysis of the Neotorch phase 3 trial demonstrates that adding toripalimab to chemotherapy perioperatively in stage III resectable NSCLC improves tumor and nodal downstaging, reduces surgery cancellation, and significantly enhances event-free survival without increasing surgical complications.
EIF4A3-Driven Nonsense-Mediated Decay: A Novel Regulatory Axis Modulating AML1-ETO9a Dosage and Clinical Outcomes in t(8;21) Acute Myeloid Leukemia
Posted inHematology-Oncology news Oncology

EIF4A3-Driven Nonsense-Mediated Decay: A Novel Regulatory Axis Modulating AML1-ETO9a Dosage and Clinical Outcomes in t(8;21) Acute Myeloid Leukemia

This review highlights how EIF4A3-dependent nonsense-mediated mRNA decay selectively regulates the oncogenic AML1-ETO9a isoform in t(8;21) AML, influencing leukemic cell proliferation, chemosensitivity, and patient survival through an isoform-specific dosage checkpoint.